

Modeling dominant interactions that influence the pathogenesis of protein folding diseases

Santiago Schnell † ‡ ¶

University of Michigan Medical School

† Department of Molecular & Integrative Physiology

‡ Department of Computational Medicine & Bioinformatics

¶ Brehm Center for Diabetes Research

E-mail: schnells@umich.edu


Web: sitemaker.umich.edu/schnell.lab




This work has been sponsored by Brehm Center for Diabetes Research, James S. McDonnell Foundation and National Institutes of Health (F31GM0967728)




A gene is translated into a protein in the endoplasmic reticulum



There are scientists who believe that protein folding occur spontaneously



Protein folding is assisted through enzyme catalyzed chaperone/co-chaperone network




Failure in protein folding is the leading cause of many diseases, particularly in old age

Protein	Location	Disease
Insulin	ER	Diabetes
Huntingtin	Nucleus and cytosol	Huntington
α -amyloid/presenilin	ER	Alzheimer's
p53	Cytosol	Cancer
Crystalins	Cytosol	Cataracts
Prion protein	ER	Creutzfeldt-Jakob
Fribillin	ER	Marfan syndrome
Cystic fibrosis transmembrane regulator	ER	Cystic fibrosis
Collagen	ER	Osteogenesis imperfecta


In medicine, these diseases are known as protein folding diseases, conformational diseases or protein aggregation diseases.

A gene is composed of two alleles, which can be expressed as proteins at the same time



Under normal physiological conditions, cells can produce misfolding protein without mutant allele

In the mouse, 3-8% of the proinsulin is misfolded under standard physiological conditions.



No glucose stimulation


30 minutes after glucose stimulation

C = Cell
M = Medium

An increase in the expression of misfolded protein causes a loss-of-function disease


The mouse expresses four alleles of proinsulin. By changing one allele with a mutant misfolding proinsulin, native insulin is not secreted (loss-of-function)

This causes a phenotype of diabetes known as Type 1b diabetes



Aggregation is a proximal event in conformation diseases and is characterized by the gain-of-function disease and lost-of-function disease

There is a threshold of misfolding protein expression, which triggers the sudden aggregation of proinsulin (gain-of-function) and decrease in insulin (lost-of-function).




Liu et al. *Proc. Natl. Acad. Sci. USA* 2007; **204**: 15841-15846

The threshold behavior occurs when 8 to 25% of the total pro-insulin is in its misfolded configuration.

The expression of protein folding disease exhibit a threshold phenomenon

Huntington's disease


Polyglutamine (polyQ) expansion in the huntingtin protein




The expression of protein folding disease exhibit a threshold phenomenon

Huntington's disease

Polyglutamine (polyQ) expansion in the huntingtin protein






Artwork by Erin Shellman

I will now present a general model describing the wild-type (normal) protein disappearance (loss-of-function) through direct or indirect interaction with misfolded protein to explore potential treatments for protein folding diseases

Sandefur & Schnell *Biophysical Journal*
2011; **100**: 1864-1873

We model normal isomers disappearance and protein aggregation as a continuous flow reaction in the endoplasmic reticulum

1.



N: normal isomers
(unfolded and folded proteins)

M: misfolded isomer

t_i : residence time in the ER

$R(N, M)$ reaction rate

The mathematical formulation of the continuous reactor model is

2. Applying mass action

$$\frac{dN}{dt} = \frac{N_0 - N}{t_N} - R(N, M) \quad (1)$$

$$\frac{dM}{dt} = \frac{M_0 - M}{t_M} + R(N, M)$$

At steady-state

$$\frac{N_0}{t_N} + \frac{M_0}{t_M} = \frac{N}{t_N} + \frac{M}{t_M} \quad (2)$$

The mathematical formulation of the continuous reactor model is

2. Applying mass action

$$\frac{dN}{dt} = \frac{N_0 - N}{t_N} - R(N, M)$$

$$\frac{dM}{dt} = \frac{M_0 - M}{t_M} + R(N, M)$$

(1)

The problem now is to determine a rate function $R(N, M)$ representative of misfolding and aggregation reactions

At steady-state

$$\frac{N_0}{t_N} + \frac{M_0}{t_M} = \frac{N}{t_N} + \frac{M}{t_M}$$

(2)

We mined the literature for all reported protein misfolding and aggregation reaction mechanisms



+




Aggmod – Repository of protein aggregation reaction
<http://aggmod.ccmb.umich.edu>

We mined the literature for all reported protein misfolding and aggregation reaction mechanisms



+



- Unique mechanisms (18/120)
- Duplicate mechanisms (35/120)
- No mechanism (67/120)

Aggmod – Repository of protein aggregation reaction
<http://aggmod.ccmb.umich.edu>

The main source of misfolded isomer is the conversion of normal isomers into misfolded isomers

In misfolding and aggregation reactions the misfolded isomer “sequesters” normal isomer in the endoplasmic reticulum to form aggregates



We find that majority of the mechanism can be described with the phenomenological overall reaction



$$R(N, M) = kN^n M^m \quad (3)$$

<http://aggmod.ccmb.umich.edu>

The overall reaction can represent, for example, an associate-limited aggregation mechanism and other aggregation mechanisms



$$R(N, M) \propto NM^2$$

if $k_{-1} \ll k_1$ and $k_{-1} \gg k_2$

We reduce our mathematical description to the extend of the reaction

Substituting (3) in (1)-(2), the normal concentration at steady state is

$$\frac{N_0 - N}{t_N} - kN^n \left[\frac{t_M}{t_N} (N_0 - N) + M_0 \right]^m = 0$$

Defining the extend of the reaction, $x = 1 - \frac{N}{N_0}$

we obtained the nondimensional expression:

$$\underbrace{\tau_u^{-1} x}_{\text{Flow } y_f(x)} - \underbrace{(1-x)^n (\tau_r x + \theta)^m}_{\text{Reaction rate } y_r(x)} = 0$$

with

$$\tau_u^{-1} = \frac{1}{t_N k N_b^{n+m-1}}$$

$$\tau_r = \frac{t_M}{t_N}$$

$$\theta = \frac{M_0}{N_0}$$

Non-dimensional normal residence time

Ratio of residence times

Ratio of basal concentrations


The parameters of our model can be controlled experimentally

$$\tau_u^{-1} = \frac{1}{t_N k N_b^{n+m-1}}$$

Non-dimensional normal residence time

$$\tau_r = \frac{t_M}{t_N}$$


Ratio of residence times



Introducing pharmacological chaperones accelerates residence time

$$\theta = \frac{M_0}{N_0}$$


Ratio of basal concentrations



Molecular engineering approaches allow differential expression of proteins

m

Stoichiometric coefficient of reaction



Protein misfolding and aggregation inhibitors reduce stoichiometry of reaction

We can now investigate the steady state behavior by looking at the flow and reaction rates

Model equation at steady state:

$$\underbrace{\tau_u^{-1} x}_{\text{Flow } y_f(x)} - \underbrace{(1-x)^n (\tau_r x + \theta)^m}_{\text{Reaction rate } y_r(x)} = 0$$

Note that $y_r(x)$ is a polynomial of order $(n + m)$. We need to understand its shape for $x = [0,1]$.

We can estimate the critical points of $y_r'(x) = 0$ as


$$x = \left\{ -\frac{\theta}{\tau_r}, 1 - \frac{n(\tau_r + \theta)}{\tau_r(n + m)}, 1 \right\}$$

Using the second derivative test, we determine that $y_r(x)$ is concave downwards and has a maximum at the critical point:



$$x = 1 - \frac{n(\tau_r + \theta)}{\tau_r(n + m)}$$

The model can exhibit bistability with changes in the ratio of basal isomers concentrations

Although the reaction is of $(n+m)$ th order, it can have up to 3 physically realistic steady-states.




The steady state of the model changes with the normal protein residence time in the ER




The threshold behavior depends on τ_u and basal isomer inflow rates

We define the basal isomer inflow rates as: $\lambda = \frac{\theta}{\tau_r} = \frac{[M_0]/t_M}{[N_0]/t_N}$



We discovered that the onset and rescue from conformational diseases is controlled by three parameters




τ : Transition time in ER; λ : unfolded-misfolded ratio; m : stoichiometry of reaction

Our model suggest that increasing the expression of normal insulin can rescue animals from diabetes


Experiment 1:

Rescuing pre-diabetic animals by preventive injection of insulin



Treatment of pre-diabetic animals with insulin shows a reduction in the amount of misfolding proinsulin

I. Hodish..., P. Arvan (2011) *Diabetes* 60, 2092-2101




~40% of β -cell with insulin treatment show misfolding proinsulin accumulation with limited insulin staining.

~60% of β -cell with insulin treatment show limited misfolding proinsulin staining.

Our model suggest that increasing the expression of normal insulin can rescue animals from diabetes


Experiment 2:

Genetic engineered 293T cell lines with wild-type and mutant proinsulin



Rescue of mutant proinsulin by wild-type proinsulin in tissue of animal model


J. Wright..., P. Arvan (2013) *J. Clin. Invest.* **123**, 3124–3134




Wright et al., Fig. 5

Secretory rescue by wild type proinsulin is restricted to a subset of mutants for type 1b (MIDY)


J. Wright..., P. Arvan (2013) *J. Clin. Invest.* **123**, 3124–3134



The limitation of our model is that we employed a generic and phenomenological reaction rate




Each mutant can have a different misfolding and aggregation pathway, so the universal rate is limited



Now we are characterizing proinsulin misfolding and aggregation reactions for each mutant to understand rescue mechanisms



+



- Unique mechanisms (18/120)
- Duplicate mechanisms (35/120)
- No mechanism (67/120)

Aggmod – Repository of protein aggregation reaction
<http://aggmod.ccmb.umich.edu>

Acknowledgements

Conformational diseases

Schnell Lab

Conner Sandefur

Michael Bell

Marcio Mourao

Arvan Lab

Ming Lui

Israel Hodish

Jordan Wright

Funding

UM Center for Protein Folding Diseases

James S. McDonnell Foundation

NIH/NIGMS F31GM0967728

William Brehm Endowment

Metabolism, obesity and cancer

Schnell Lab

Michelle Wynn

Erin Shellman

Firas Midani

Merajver Lab

Burant Lab

Funding

NIH/NIDDK R25 DK088752

NIH/NIDDK U24 DK097153

UM CCMB Pilot Grant 2011

James S. McDonnell Foundation

ER Stress and diabetes

Schnell Lab

Samantha Thomas

Caroline Adams

Pietropaollo Lab

Funding

NIH/NIDDK DP3 DK101083

NIH/NIDDK R01 DK053456

William Brehm Endowment

Developmental Biology

Schnell Lab

Michelle Wynn

Alexis Carulli

Kulesa Lab

Gumucio Lab

Samuelson Lab

Funding

Stowers Institute Endowment

NIH/NIDDK R01DK089933

NIH/NIDDK F30DK095517